Fig. 6

Hm@TSA/As-MOF increased the abundance of TILs by normalising tumour blood vessels. Tumour blood vessels were labelled with a CD31 antibody (scale bar = 100 μm) (A). The morphologies of tumour blood vessels were observed by micro CT (B). The levels of VEGF in tumour tissues were evaluated via immunohistochemical analysis (scale bar = 100 μm) (C). The pericyte coverage rate of tumour blood vessels was evaluated via NG2 staining (scale bar = 20 μm) (D). Dextran and lectin were used to evaluate the leakage (E) and perfusion (F) of tumour vessels, respectively (scale bar = 10 μm). The levels of CD3⁺ TILs (G), CD4⁺ TILs (H) and CD8⁺ TILs (I) were evaluated via flow cytometry (n = 3). Data are expressed as the mean ± SD (*, p < 0.05; **, p < 0.01; ***, p < 0.001; two-tailed Student’s t-test)